WuXi AppTec Aiming To Relist Biologics Unit In Hong Kong IPO
This article was originally published in PharmAsia News
Executive Summary
WuXi AppTec is planning to spin out its biologics CRO/CMO unit in a Hong Kong IPO that is likely to raise at least $367m, sources have confirmed. The new funding would provide the fast-growing Wuxi Biologics subsidiary with the freedom and resources to make its own pipeline portfolio decisions.